Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-06804103 |
Synonyms | |
Therapy Description |
PF-06804103 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to Aur0101, which delivers the cytotoxic drug to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of ERBB2 (HER2)-expressing tumors (Cancer Res July 1 2018 (78) (13 Supplement) 818, PMID: 32747418, PMID: 32710210). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-06804103 | PF06804103|PF 06804103 | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 | PF-06804103 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody linked to Aur0101, which delivers the cytotoxic drug to ERBB2 (HER2)-expressing tumor cells, potentially resulting in decreased growth of ERBB2 (HER2)-expressing tumors (Cancer Res July 1 2018 (78) (13 Supplement) 818, PMID: 32747418, PMID: 32710210). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03284723 | Phase I | Letrozole + Palbociclib + PF-06804103 PF-06804103 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | Terminated | USA | ITA | ESP | AUS | 2 |